<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653899</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024049</org_study_id>
    <nct_id>NCT01653899</nct_id>
  </id_info>
  <brief_title>Caspase Inhibition in Islet Transplantation</brief_title>
  <official_title>Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conatus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Investigator Initiated, Phase I/II study, where Type 1 diabetic participants will&#xD;
      receive a 14 day oral treatment of the investigational caspase inhibitor drug IDN-6556&#xD;
      following their first islet transplant. Two pilot studies are proposed to establish the&#xD;
      optimal safety and efficacy dose of IDN-6556 (25 mg twice daily (Pilot 1) or a loading dose&#xD;
      of 100 mg two hours prior to transplantation, then two 50 mg doses following transplant (Day&#xD;
      0) (Pilot 2). This will be followed by 50 mg three times daily). Participants of both pilot&#xD;
      studies will receive islet cell transplants under the University of Alberta's&#xD;
      standard-of-care therapy.&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
        1. To determine the proportion of subjects treated with IDN-6556 who achieve and maintain&#xD;
           insulin independence after the first or subsequent islet transplant.&#xD;
&#xD;
        2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate&#xD;
           immunological protection against both allo- and autoimmunity of islet transplant&#xD;
           recipients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant</measure>
    <time_frame>3 years post-initial transplant</time_frame>
    <description>The primary objective of this protocol is to assess the safety of the IDN-6556 caspase inhibitor in adult Type 1 diabetic participants receiving their first islet transplant. A tracking log will document adverse events and unexpected complications associated with IDN-6556 using a grading classification as per protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. To determine the proportion of subjects treated with IDN-6556 who achieve and maintain insulin independence after the first or subsequent islet transplant.</measure>
    <time_frame>3 years post-initial transplant</time_frame>
    <description>The proportion of study participants achieving and maintaining insulin independence (c-peptide, HbA1c level) with good glycemic control (blood sugar measurement) at Day 90 and 1, 2, 3 years post-initial islet transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. To obtain preliminary data on the efficacy of IDN-6556 to maintain adequate immunological protection against both allo- and autoimmunity of islet transplant recipients.</measure>
    <time_frame>3 years post-initial transplant</time_frame>
    <description>Immune monitoring for HLA and panel reactive antibody will be performed using serum samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>IDN-6556</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDN-6556</intervention_name>
    <description>14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.</description>
    <arm_group_label>IDN-6556</arm_group_label>
    <other_name>Emricasan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible the participant must have had T1DM for more than 5 years, complicated by at&#xD;
        least 1 of the following situations that persist despite intensive insulin management&#xD;
        efforts:&#xD;
&#xD;
          -  Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic&#xD;
             symptoms at plasma glucose levels &lt; 3.0 mmol/L, indicated by, 1 or more episodes of&#xD;
             severe hypoglycemia requiring third party assistance within 12 months, a Clarke score&#xD;
             ≥ 4, HYPO score ≥ 1,000, lability index (LI) ≥ 400 or combined Hypo/LI &gt; 400/300&#xD;
&#xD;
          -  Metabolic instability, characterized by erratic blood glucose levels that interfere&#xD;
             with daily activities and or 1 or more hospital visits for diabetic ketoacidosis over&#xD;
             the last 12 months.&#xD;
&#xD;
        Participants must be capable of understanding the purpose and risks of the study and must&#xD;
        sign a statement of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe co-existing cardiac disease, characterized by any one of these conditions: (a)&#xD;
             recent myocardial infarction (within past 6 months); (b) left ventricular ejection&#xD;
             fraction &lt; 30%; or (c) evidence of ischemia on functional cardiac exam.&#xD;
&#xD;
          2. Active alcohol or substance abuse, to include cigarette smoking (must be abstinent for&#xD;
             6 months prior to transplant).&#xD;
&#xD;
          3. Psychiatric disorder making the subject not a suitable candidate for transplantation,&#xD;
             (e.g., schizophrenia, bipolar disorder, or major depression that is unstable or&#xD;
             uncontrolled on current medication).&#xD;
&#xD;
          4. History of non-adherence to prescribed regimens.&#xD;
&#xD;
          5. Active infection including Hepatitis C, Hepatitis B, HIV, TB (subjects with a positive&#xD;
             PPD performed within one year of enrollment, and no history of adequate&#xD;
             chemoprophylaxis).&#xD;
&#xD;
          6. Any history of or current malignancies except squamous or basal skin cancer.&#xD;
&#xD;
          7. BMI &gt; 35 kg/m2 at screening visit.&#xD;
&#xD;
          8. Age less than 18 or greater than 68 years.&#xD;
&#xD;
          9. Measured glomerular filtration rate (GFR) &lt; 60 mL/min/1.73 m2.&#xD;
&#xD;
         10. Presence or history of macroalbuminuria (&gt; 300 mg/g creatinine).&#xD;
&#xD;
         11. Clinical suspicion of nephritic (hematuria, active urinary sediment) or rapidly&#xD;
             progressing renal impairment (e.g. Increase in serum creatinine of 25% within the last&#xD;
             3-6 months).&#xD;
&#xD;
         12. Baseline Hb &lt; 105g/L (&lt; 10.5 g/dL) in women, or &lt; 120 g/L (&lt; 12 g/dL) in men.&#xD;
&#xD;
         13. Baseline screening liver function tests outside of normal range, with the exception of&#xD;
             uncomplicated Gilbert's Syndrome. An initial LFT panel with any values &gt; 1.5 times the&#xD;
             upper limit of normal (ULN) will exclude a patient without a re-test; a re test for&#xD;
             any values between ULN and 1.5 times ULN should be made, and if the values remain&#xD;
             elevated above normal limits, the patient will be excluded.&#xD;
&#xD;
         14. Untreated proliferative retinopathy.&#xD;
&#xD;
         15. Positive pregnancy test, intent for future pregnancy or male subjects' intent to&#xD;
             procreate, failure to follow effective contraceptive measures, or presently breast&#xD;
             feeding.&#xD;
&#xD;
         16. Previous transplant or evidence of significant sensitization on PRA (at the discretion&#xD;
             of the investigator).&#xD;
&#xD;
         17. Insulin requirement &gt; 1.0 U/kg/day&#xD;
&#xD;
         18. HbA1C &gt; 12%.&#xD;
&#xD;
         19. Uncontrolled hyperlipidemia [fasting LDL cholesterol &gt; 3.4 mmol/L (133 mg/dL), treated&#xD;
             or untreated; and/or fasting triglycerides &gt; 2.3 mmol/L (90 mg/dL)].&#xD;
&#xD;
         20. Under treatment for a medical condition requiring chronic use of steroids.&#xD;
&#xD;
         21. Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR&#xD;
             &gt; 1.5.&#xD;
&#xD;
         22. Untreated Celiac disease.&#xD;
&#xD;
         23. Patients with Graves disease will be excluded unless previously adequately treated&#xD;
             with radioiodine ablative therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.M. James Shapiro, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>James Shapiro</investigator_full_name>
    <investigator_title>Director, Clinical Islet Transplant Program</investigator_title>
  </responsible_party>
  <keyword>Type I Diabetes</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

